Evidence map›Paper›PMID 26365877›Full record

ArticlePharmacological research2015

Disabling mitochondrial reprogramming in cancer.

M Cecilia Caino, Dario C Altieri

Open access · greenAbstract read
In one paragraph

Article in Pharmacological research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

M Cecilia CainoProstate Cancer Discovery and Development Program, Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, United States.
Dario C AltieriProstate Cancer Discovery and Development Program, Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, United States. Electronic address: daltieri@wistar.org.
The Wistar Institute · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Role of Runx2 in prostate tumorigenesis and metastasisP01CA140043 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2010 to 2021
$12.2M
CONTROL OF APOPTOSIS IN CANCER BY SURVIVINR01CA078810 · NCI · YALE UNIVERSITY · PI ALTIERI, DARIO C · 1998 to 2017
$5.5M
(PQC2) Plasticity Of The.PI3K Network In Early DormancyR01CA190027 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2014 to 2016
$1.2M
Mitochondrial Hsp90s Regulation of Tumor Bioenergetics and MetastasisF32CA177018 · NCI · WISTAR INSTITUTE · PI CAINO, MARIA CECILIA · 2013 to 2015
$171k
NCI NIH HHS CA190027NCI NIH HHS F32 CA177018NCI NIH HHS F32CA177018NCI NIH HHS P01 CA140043NCI NIH HHS P01CA140043NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA078810NCI NIH HHS R01 CA190027NCI NIH HHS R01CA78810
6 · The paper itself

Abstract

Recent studies have demonstrated that tumor cells exposed to molecular therapy with PI3K antagonists redistribute their mitochondria to the peripheral cytoskeleton, fueling membrane dynamics, turnover of focal adhesion complexes and increased tumor cell motility and invasion. Although this process paradoxically increases metastatic propensity during molecular therapy, it also emphasizes a critical role of regional mitochondrial bioenergetics in tumor metabolic reprogramming and may offer prime therapeutic opportunities to prevent disseminated disease.

Indexed as

Antineoplastic AgentsCell AdhesionCell MovementCytoskeletonFocal AdhesionsHumansMitochondriaNeoplasmsPhosphatidylinositol 3-KinasesAntineoplastic AgentsPhosphatidylinositol 3-KinasesDrug resistanceHsp90MetastasisMitochondriaPI3K

Identifiers

PMID26365877
PMCPMC4684442
OpenAlexW1719328405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.